Status and phase
Conditions
Treatments
About
Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.
Full description
Patients in the camrelizumab group were treated with camrelizumab with the dose of 200mg on day 1, repeated every 21 days.Patients in the combination group were treated with MWA in the primary tumor followed by camrelizumab with the dose of 200mg on day 1, repeated every 21 days.
The primary end point is overall survival. The second end points include progression free survival, objective response rate and safety.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
200 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Zhigang Wei; Xin Ye
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal